Omeprazole

(oh-MEH-pray-ZAHL)

Trade Name(s):
Prilosec
  • Capsules, delayed-release
  • 10 mg
  • Capsules, delayed-release
  • 20 mg
  • Capsules, delayed-release
  • 40 mg

    Losec
    Indicates Canadian trade names.

    Class:  GI

      Action:
    Suppresses gastric acid secretion by blocking "acid (proton) pump" within gastric parietal cell.

      Indications:
    Short-term treatment of active duodenal ulcer, gastroesophageal reflux disease (GERD), including erosive esophagitis and symptomatic GERD; long-term treatment of pathologic hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas, systemic mastocytosis); to maintain healing of erosive esophagitis; in combination with clarithromycin to eradicate H. pylori, use clarithromycin and amoxicillin in combination with omeprazole in patients with a 1-yr history of duodenal ulcers or active duodenal ulcers to eradicate H. pylori; short-term treatment of active benign gastric ulcer. Unlabeled use(s):Posterior laryngitis; enhanced efficacy of pancreatin for treatment of steatorrhea in cystic fibrosis.

      Contraindications:
    Standard considerations.

      Route/Dosage:

    Active Duodenal Ulcer

    Adults:
    PO 20 mg/day for 4 to 8 wk.

    Erosive Esophagitis

    Adults:
    PO 20 mg/day for 4 to 8 wk.

    Maintenance: 20 mg daily.

    Pathologic Hypersecretory Conditions

    Adults:
    PO Initial dose: 60 mg/day. Doses up to 120 mg tid have been given. Divide daily doses > 80 mg.

    H. pylori

    Adults (triple therapy):
    PO 20 mg omeprazole plus clarithromycin 500 mg plus amoxicillin 1000 mg each given bid for 10 days; continue omeprazole 20 mg daily for an additional 18 days if an ulcer is present at start of therapy.

    Adults (dual therapy):
    PO 40 mg omeprazole once daily plus clarithromycin 500 mg tid for 14 days; continue omeprazole 20 mg daily for an additional 14 days if an ulcer is present at start of therapy.

    Gastric ulcer

    Adults:
    PO 40 mg once daily for 4 to 8 wk.

    GERD

    Adults (without esophageal lesions):
    PO 20 mg daily for 4 wk.

    Adults (with erosive esophagitis):
    PO 20 mg daily for 4 to 8 wk.

      Interactions:

    Benzodiazepines: Clearance of benzodiazepines may be decreased.

    Clarithromycin: Serum concentrations of clarithromycin and omeprazole may be increased.

    Drugs depending on gastric pH for bioavailability (eg, ketoconazole, iron salts, ampicillin): Absorption of these drugs may be affected.

    Phenytoin: Decreased plasma clearance and increased half-life phenytoin.

    Warfarin: Prolonged warfarin elimination.

      Lab Test Interferences:
    None well documented.

      Adverse Reactions:

    CV:
    Angina; tachycardia; bradycardia; palpitation.
    CNS:
    Headache; dizziness.
    DERM:
    Rash.
    GI:
    Diarrhea; abdominal pain; acid regurgitation; nausea; vomiting; constipation; flatulence.
    RESP:
    Cough; upper respiratory infection.
    OTHER:
    Asthenia; back pain.

      Precautions:

    Pregnancy: Category C.

    Lactation: Undetermined.

    Children: Safety and efficacy in children not established.


    Patient Care Considerations

      Administration/Storage:

      Assessment/Interventions:


    OVERDOSAGE: SIGNS & SYMPTOMS
    Confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, dry mouth

      Patient/Family Education:


    AtoZ Drug Facts · Copyright©2000 by Facts and Comparisons